- Home
- RPRX
RPRX
Royalty Pharma plc
as 11-05-2025 4:00pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 16.2B | IPO Year: | 2020 |
| Target Price: | $46.00 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.77 | EPS Growth: | -30.73 |
| 52 Week Low/High: | $24.05 - $41.00 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,349,553,000 | Revenue Growth: | 3.69% |
| Revenue Growth (this year): | 36.16% | Revenue Growth (next year): | 2.04% |
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Norden Gregory | RPRX | N/A | Aug 11 '25 | Sell | $36.23 | 33,500 | $1,213,748.55 | 194,848 |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
StockStory
8 days ago
2 Reasons to Avoid RPRX and 1 Stock to Buy Instead
Insider Monkey
9 days ago
What Do Analysts Think About Royalty Pharma Plc (RPRX)?
PR Newswire
9 days ago
Balancing Innovation and Income: A2 Fund Shares 2026 Market Outlook Following 75% YTD Fund Growth
Simply Wall St.
24 days ago
Royalty Pharma (RPRX) Valuation: Is There More Upside After This Year’s 40% Rally?
StockStory
24 days ago
3 Healthcare Stocks We Keep Off Our Radar
GlobeNewswire
a month ago
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
Insider Monkey
a month ago
Revolution Medicines, Inc. (RVMD) Insider Sells Shares
Compare RPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.